NCT02896335 2026-03-12
Palbociclib and Pembrolizumab In Central Nervous System Metastases
Massachusetts General Hospital
Phase 2 Recruiting
Clinical Trials
7 trialsNCT05432518 2025-04-25
Pilot Trial for Treatment of Recurrent Glioblastoma
AHS Cancer Control Alberta
Phase EARLY_PHASE1 Recruiting
NCT02530320 2024-11-22
Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
Grupo Español de Investigación en Neurooncología
Phase 2 Completed
NCT03158389 2023-09-28
N²M²
University Hospital Heidelberg
Phase 1/2 Completed
NCT04334330 2022-05-02
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
Sun Yat-sen University
Phase 2 Unknown
NCT04585724 2021-10-18
Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
Emory University
Phase 1 Withdrawn
NCT01227434 2015-07-17
PD0332991
University of California, San Francisco
Phase 2 Terminated